Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)

NCT03345082 is registered in ClinicalTrials.gov with Opthea Limited as lead sponsor.

NCT NCT03345082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03345082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Lead sponsor
Opthea Limited
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2017
Completion date
May 14, 2019
Enrollment
366 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration